AbCellera Biologics (ABCL) Competitors $3.89 -0.14 (-3.47%) Closing price 04:00 PM EasternExtended Trading$3.91 +0.02 (+0.51%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. RYTM, KRYS, CYTK, ZLAB, PTCT, MRUS, ACLX, ACAD, SWTX, and RAREShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. Its Competitors Rhythm Pharmaceuticals Krystal Biotech Cytokinetics Zai Lab PTC Therapeutics Merus Arcellx ACADIA Pharmaceuticals SpringWorks Therapeutics Ultragenyx Pharmaceutical Rhythm Pharmaceuticals (NASDAQ:RYTM) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend RYTM or ABCL? Rhythm Pharmaceuticals currently has a consensus price target of $78.07, indicating a potential upside of 19.85%. AbCellera Biologics has a consensus price target of $7.50, indicating a potential upside of 92.80%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in RYTM or ABCL? 61.4% of AbCellera Biologics shares are owned by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer RYTM or ABCL? In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 11 mentions for Rhythm Pharmaceuticals and 8 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.66 beat Rhythm Pharmaceuticals' score of 0.55 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is RYTM or ABCL more profitable? Rhythm Pharmaceuticals has a net margin of -123.26% compared to AbCellera Biologics' net margin of -737.56%. AbCellera Biologics' return on equity of -15.98% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-123.26% -739.62% -44.27% AbCellera Biologics -737.56%-15.98%-12.38% Which has more volatility & risk, RYTM or ABCL? Rhythm Pharmaceuticals has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Which has better earnings & valuation, RYTM or ABCL? AbCellera Biologics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M31.85-$260.60M-$2.81-23.18AbCellera Biologics$28.83M40.27-$162.86M-$0.56-6.95 SummaryAbCellera Biologics beats Rhythm Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-6.9520.8027.0020.10Price / Sales40.27286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book1.097.487.985.56Net Income-$162.86M-$55.04M$3.16B$248.40M7 Day Performance11.46%5.44%3.69%6.04%1 Month Performance59.43%2.38%2.91%7.69%1 Year Performance41.45%5.53%34.30%20.97% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.5457 of 5 stars$3.89-3.5%$7.50+92.8%+49.8%$1.20B$28.83M-6.95500News CoverageAnalyst ForecastRYTMRhythm Pharmaceuticals3.4373 of 5 stars$63.19+0.7%$77.31+22.3%+57.0%$4.02B$130.13M-22.49140News CoverageAnalyst ForecastKRYSKrystal Biotech4.4838 of 5 stars$137.46-1.0%$211.13+53.6%-24.2%$3.97B$333.45M33.04210CYTKCytokinetics3.8988 of 5 stars$33.04-0.4%$70.92+114.7%-39.9%$3.95B$18.47M-6.25250ZLABZai Lab3.381 of 5 stars$34.97+0.7%$54.28+55.2%+104.8%$3.88B$398.99M-14.041,869Gap UpPTCTPTC Therapeutics4.2862 of 5 stars$48.84-2.0%$65.00+33.1%+55.1%$3.87B$1.77B7.501,410MRUSMerus2.0892 of 5 stars$52.60-0.7%$84.64+60.9%-1.4%$3.64B$54.73M-12.8937Positive NewsACLXArcellx2.2837 of 5 stars$65.85+0.8%$111.23+68.9%+21.1%$3.63B$107.94M-22.0280ACADACADIA Pharmaceuticals4.6689 of 5 stars$21.57-2.5%$27.88+29.2%+29.4%$3.61B$996.28M15.74510SWTXSpringWorks Therapeutics1.5381 of 5 stars$46.99+0.0%$52.57+11.9%N/A$3.54B$191.59M-13.78230RAREUltragenyx Pharmaceutical4.0595 of 5 stars$36.36-0.4%$87.00+139.3%-3.1%$3.44B$590.69M-6.181,294 Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors Krystal Biotech Competitors Cytokinetics Competitors Zai Lab Competitors PTC Therapeutics Competitors Merus Competitors Arcellx Competitors ACADIA Pharmaceuticals Competitors SpringWorks Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
